Karim Fizazi, MD, PhD

Christopher Wallis, MD, PhD, FRCSC

GU Oncology Now

Karim Fizazi, MD, PhD, Gustave Roussy Cancer Institute, and Christopher Wallis, MD, PhD, University of Toronto, detail the latest updates regarding the phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with mCRPC harboring homologous recombination repair gene alterations.The updated results of TALAPRO-2 has since led to the <a href="https://guoncologynow.com/post/fda-approves-talazoparib-in-combination-with-enzalutamide-for-hrr-mutated-mcrpc" target="_blank" rel="noopener">FDA approval of talazoparib in combination with enzalutamide for HRR-Mutated mCRPC</a>.<a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.

Drs. Fizazi, Wallis on Updated Data from TALAPRO-2

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Fizazi and Wallis detail the latest updates regarding the phase 3 study of talazoparib plus enzalutamide for patients with mCRPC and HRR gene alterations.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe